Why test for RAS and BRAF mutation in colorectal cancer (CRC)?
Clinical guidelines recommend expanded RAS testing to select metastasised CRC (mCRC) patients eligible for anti-EGFR therapy.1,2 For all patients with stage IV metastatic CRC at diagnosis, BRAF mutation analysis is also recommended as an indicator of poor prognosis.2 The potential clinical utility of BRAF inhibitors in combination with anti-EGFR therapy is currently being investigated in clinical trials.
To test for these clinically actionable mutations, minimally invasive liquid biopsy has become a valuable tool. It delivers real-time and unbiased information supporting treatment decisions and monitoring of the patient’s response to treatment or the emergence of resistance.3
The Sysmex Inostics’ OncoBEAM RAS CRC IVD kit provides unparalleled sensitivity and thereby ensures reliable detection of RAS mutations from plasma samples, also at very low mutant allele fractions (MAFs). This provides guidance for physicians regarding therapy selection. Using the OncoBEAM RAS CRC IVD kit for monitoring RAS mutations during anti-EGFR therapy may provide early insight into predicting clinical outcomes in mCRC patients as well.3.6
The clinical value of the OncoBEAM RAS CRC IVD kit has been demonstrated in various studies and is applied worldwide in our centres of excellence for helping physicians in selecting the right therapy at the right time for the right patients.
Available products
OncoBEAM RAS CRC (IVD)
Detection of 34 RAS mutations – 16 mutations in KRAS codons 12, 13, 59, 61, 117, 146 and 18 mutations in NRAS codons 12, 13, 59, 61, 117, 146 – in cell-free DNA extracted from 3 mL of plasma. The test is intended to aid clinicians in determining the potential benefit of anti-epidermal growth factor receptor (EGFR) therapy for colorectal cancer patients.
OncoBEAM BRAF (RUO*)
Detection of BRAF V600E mutation in cell-free DNA extracted from 3 mL of plasma.
*For research use only. Any in vitro diagnostics purpose has not been established by the manufacturer.
